
Gianfranco Cicoria

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/616074/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 365-84.	1.0	109
2	Engineered porphyrin loaded core-shell nanoparticles for selective sonodynamic anticancer treatment. Nanomedicine, 2015, 10, 3483-3494.	3.3	57
3	Automation synthesis modules review. Applied Radiation and Isotopes, 2013, 76, 38-45.	1.5	50
4	Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2122-2130.	6.4	42
5	Assessment of radionuclidic impurities in 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG) routine production. Applied Radiation and Isotopes, 2008, 66, 295-302.	1.5	40
6	Synthesis and quality control of 68Ga citrate for routine clinical PET. Nuclear Medicine Communications, 2009, 30, 542-545.	1.1	38
7	Usefulness of 64Cu-ATSM in Head and Neck Cancer. Clinical Nuclear Medicine, 2014, 39, e59-e63.	1.3	36
8	In-house cyclotron production of high-purity Tc-99m and Tc-99m radiopharmaceuticals. Applied Radiation and Isotopes, 2018, 139, 325-331.	1.5	35
9	Prediction of 89Zr production using the Monte Carlo code FLUKA. Applied Radiation and Isotopes, 2011, 69, 1134-1137.	1.5	32
10	Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With 64Cu-ATSM PET/CT. Clinical Nuclear Medicine, 2016, 41, e87-e92.	1.3	32
11	A solvent-extraction module for cyclotron production of high-purity technetium-99m. Applied Radiation and Isotopes, 2016, 118, 302-307.	1.5	29
12	Production of Ga-68 with a General Electric PETtrace cyclotron by liquid target. Physica Medica, 2018, 55, 116-126.	0.7	29
13	Production of ⁶⁷ Cu by enriched ⁷⁰ Zn targets: first measurements of formation cross sections of ⁶⁷ Cu, ⁶⁴ Cu, ⁶⁷ Ga, ⁶⁶ Ga, ^{69m} Zn and ⁶⁵ Zn in interactions of ⁷⁰ Zn with protons above 45 MeV. Radiochimica Acta, 2020, 108, 593-602.	1.2	28
14	Synthesis of oncological [11C]radiopharmaceuticals for clinical PET. Nuclear Medicine and Biology, 2012, 39, 447-460.	0.6	24
15	Accurate Monte Carlo modeling of cyclotrons for optimization of shielding and activation calculations in the biomedical field. Radiation Physics and Chemistry, 2015, 116, 231-236.	2.8	23
16	Innovative Target for Production of Technetium-99m by Biomedical Cyclotron. Molecules, 2019, 24, 25.	3.8	21
17	Radioisotopic purity and imaging properties of cyclotron-produced ^{99m} Tc using direct ¹⁰⁰ Mo(<i>p</i> ,2 <i>n</i>) reaction. Physics in Medicine and Biology, 2018, 63, 185021.	3.0	17
18	Neutron production in the operation of a 16.5MeV PETrace cyclotron. Progress in Nuclear Energy, 2008, 50, 939-943.	2.9	16

GIANFRANCO CICORIA

#	Article	IF	CITATIONS
19	Radiolabelling, quality control and radiochemical purity assessment of the Octreotide analogue 68Ga DOTA NOC. Applied Radiation and Isotopes, 2008, 66, 1091-1096.	1.5	16
20	Assessment of the neutron dose field around a biomedical cyclotron: FLUKA simulation and experimental measurements. Physica Medica, 2016, 32, 1602-1608.	0.7	16
21	Some experimental studies on ⁸⁹ Zr production. Radiochimica Acta, 2011, 99, 631-634.	1.2	15
22	Generator Breakthrough and Radionuclidic Purification in Automated Synthesis of 68Ga-DOTANOC. Current Radiopharmaceuticals, 2013, 6, 72-77.	0.8	15
23	Medical Cyclotron Solid Target Preparation by Ultrathick Film Magnetron Sputtering Deposition. Instruments, 2019, 3, 21.	1.8	14
24	Accurate modeling of a DOI capable small animal PET scanner using GATE. Applied Radiation and Isotopes, 2013, 75, 105-114.	1.5	13
25	64Cu and fluorescein labeled anti-miRNA peptide nucleic acids for the detection of miRNA expression in living cells. Scientific Reports, 2019, 9, 3376.	3.3	13
26	Activation studies for the decommissioning of PET cyclotron bunkers by means of Monte Carlo simulations. Radiation Physics and Chemistry, 2020, 174, 108966.	2.8	13
27	Development of a modular system for the synthesis of PET [11C]labelled radiopharmaceuticals. Applied Radiation and Isotopes, 2009, 67, 1869-1873.	1.5	12
28	Activation studies of a PET cyclotron bunker. Radiation Physics and Chemistry, 2019, 161, 48-54.	2.8	12
29	Radiation emission dose from patients administered 90Y-labelled radiopharmaceuticals: comparison of experimental measurements versus Monte Carlo simulation. Nuclear Medicine Communications, 2008, 29, 1100-1105.	1.1	11
30	Experimental measurement and Monte Carlo assessment of Argon-41 production in a PET cyclotron facility. Physica Medica, 2015, 31, 991-996.	0.7	10
31	Transglutaminase-mediated conjugation and nitride-technetium-99m labelling of a bis(thiosemicarbazone) bifunctional chelator. Journal of Inorganic Biochemistry, 2018, 183, 18-31.	3.5	10
32	Characterization of 41Ar production in air at a PET cyclotron facility. Modern Physics Letters A, 2017, 32, 1740014.	1.2	9
33	Radiation Protection Studies for Medical Particle Accelerators using Fluka Monte Carlo Code. Radiation Protection Dosimetry, 2017, 173, 185-191.	0.8	9
34	Radiotherapy-induced malfunctions of cardiac implantable electronic devices in cancer patients. Internal and Emergency Medicine, 2020, 15, 967-973.	2.0	9
35	Monte Carlo modeling provides accurate calibration factors for radionuclide activity meters. Applied Radiation and Isotopes, 2014, 94, 158-165.	1.5	8
36	Early and delayed evaluation of solid tumours with 64Cu-ATSM PET/CT. Nuclear Medicine Communications, 2017, 38, 340-346.	1.1	8

#	Article	IF	CITATIONS
37	Low dose radiation 18F–fluoride PET/CT in the assessment of Unilateral Condylar Hyperplasia of the mandible: preliminary results of a single centre experience. European Journal of Hybrid Imaging, 2018, 2, 7.	1.5	7
38	Cyclotron solid targets preparation for medical radionuclides production in the framework of LARAMED project. Journal of Physics: Conference Series, 2020, 1548, 012022.	0.4	7
39	Efficiency calibration of a portable CZT detector for nondestructive activation assessment of a cyclotron bunker. Radiation Effects and Defects in Solids, 2016, 171, 705-713.	1.2	7
40	Effective production of 65Zn with a PET cyclotron. Applied Radiation and Isotopes, 2012, 70, 1590-1594.	1.5	6
41	Radiation dose around a PET scanner installation: Comparison of Monte Carlo simulations, analytical calculations and experimental results. Physica Medica, 2014, 30, 448-453.	0.7	6
42	Assessment of internal contamination hazard and fast monitoring for workers involved in maintenance operations on PET cyclotrons. Radiation Protection Dosimetry, 2011, 144, 468-472.	0.8	5
43	In vitro thrombogenicity of drug-eluting and bare metal stents. Thrombosis Research, 2020, 185, 43-48.	1.7	5
44	An HPLC and UHPLC-HRMS approach to study PSMA-11 instability in aqueous solution. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 14.	3.9	5
45	Use of 65Zn as a tracer for the assessment of purification in the 68Ga-DOTANOC synthesis. Applied Radiation and Isotopes, 2013, 80, 27-31.	1.5	4
46	The concept of minimum detectable activity of radionuclide activity meters and their suitability for routine quality control of radiopharmaceuticals. An experimental study. Applied Radiation and Isotopes, 2016, 113, 22-27.	1.5	4
47	Experimental monitoring of ozone production in a PET cyclotron facility. Applied Radiation and Isotopes, 2010, 68, 1933-1936.	1.5	3
48	An innovative gamma-ray spectrometry system using a compact and portable CZT detector for radionuclidic purity tests of PET radiopharmaceuticals. Radiation Effects and Defects in Solids, 2016, 171, 726-735.	1.2	3
49	Acceptance Tests and Quality Control of Ge/ Ga Generators. Current Radiopharmaceuticals, 2009, 2, 165-168.	0.8	3
50	Modeling of a Cyclotron Target for the Production of 11C with Geant4. Current Radiopharmaceuticals, 2018, 11, 92-99.	0.8	3
51	Undesired radionuclides in18F2production by deuterons. Radiation Effects and Defects in Solids, 2009, 164, 336-339.	1.2	2
52	Automated synthesis of [11C]meta hydroxyephedrine, a PET radiopharmaceutical for studying sympathetic innervation in the heart. , 2008, , .		1
53	A bis(thiosemicarbazone) bifunctional chelating agent for nitrido-technetium-99m and copper-64 based radiopharmaceuticals. Nuclear Medicine and Biology, 2019, 72-73, S28.	0.6	0